top of page
The Professional Network for Healthcare Experts
GENFIT outlines $1.5bn US peak-sales opportunity for MASH diagnostics platform
GENFIT says its MASH diagnostics technology could support more than $1.5 billion in peak US sales by 2033 as the market for non-invasive patient identification expands.
nuaxia
8 hours ago1 min read
UK Expands Wegovy Approval to Include MASH Treatment
The MHRA has conditionally approved Novo Nordisk’s GLP-1 therapy for adults with metabolic-associated steatohepatitis, marking another milestone in the evolution of obesity medicines.
nuaxia
Jul 73 min read
bottom of page